Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Simon

Showing results (601-610 of 732) with videos related to

Pageof 74
Sort By:
Communications Biology|April 12, 2022
Wuschel2 enables highly efficient CRISPR/Cas-targeted genome editing during rapid de novo shoot regeneration in sorghumPing Che, Emily Wu, Marissa K Simon, et al.
Journal of Hospital Medicine|October 15, 2024
Association between hospital type and length of stay and readmissions for young adults with complex chronic diseasesJeffrey Lutmer, Emily Bucholz, Katherine A Auger, et al.
Cancer|April 12, 2013
Acupuncture in the treatment of upper-limb lymphedema: results of a pilot studyBarrie R Cassileth, Kimberly J Van Zee, K Simon Yeung, et al.
Neurobiology of Aging|October 26, 2005
Somatic mitochondrial DNA mutations in single neurons and gliaIppolita Cantuti-Castelvetri, Michael T Lin, Kangni Zheng, et al.
The Journal of Infectious Diseases|September 11, 2019
Immunogenicity, Lot Consistency, and Extended Safety of rVSVΔG-ZEBOV-GP Vaccine: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study in Healthy AdultsScott A Halperin, Rituparna Das, Matthew T Onorato, et al.
The Lancet. Infectious Diseases|March 21, 2026
Safety, tolerability, and immunogenicity of a 31-valent pneumococcal conjugate vaccine (VAX-31) in healthy adults aged 50 years and older from the USA: a phase 1/2, double-blinded, active-controlled, parallel-group, dose-finding randomised clinical trialJames Wassil, Jeff Fairman, Carlos A Fierro, et al.
Vaccine|July 22, 2008
Evaluation of widely consumed botanicals as immunological adjuvantsGovind Ragupathi, K Simon Yeung, Ping-Chung Leung, et al.
Neurorehabilitation|May 1, 2023
Stakeholder perspectives on navigating the pediatric concussion experience: Exploring the needs for improved communication across the care continuumDouglas Gomez, Ann Glang, Juliet Haarbauer-Krupa, et al.
Vaccine|January 18, 2022
Lot-to-lot consistency, safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in healthy adults aged ≥50 years: A randomized phase 3 trial (PNEU-TRUE)Jakub K Simon, Nina Breinholt Staerke, Maria Hemming-Harlo, et al.
The Lancet. Infectious Diseases|December 7, 2023
Evaluating the safety, tolerability, and immunogenicity of a 24-valent pneumococcal conjugate vaccine (VAX-24) in healthy adults aged 18 to 64 years: a phase 1/2, double-masked, dose-finding, active-controlled, randomised clinical trialJames Wassil, Maggie Sisti, Jeff Fairman, et al.
Pageof 74

Showing results (601-610 of 732) with videos related to

Sort By:
Pageof 74
Communications Biology|April 12, 2022
Wuschel2 enables highly efficient CRISPR/Cas-targeted genome editing during rapid de novo shoot regeneration in sorghumPing Che, Emily Wu, Marissa K Simon, et al.
Journal of Hospital Medicine|October 15, 2024
Association between hospital type and length of stay and readmissions for young adults with complex chronic diseasesJeffrey Lutmer, Emily Bucholz, Katherine A Auger, et al.
Cancer|April 12, 2013
Acupuncture in the treatment of upper-limb lymphedema: results of a pilot studyBarrie R Cassileth, Kimberly J Van Zee, K Simon Yeung, et al.
Neurobiology of Aging|October 26, 2005
Somatic mitochondrial DNA mutations in single neurons and gliaIppolita Cantuti-Castelvetri, Michael T Lin, Kangni Zheng, et al.
The Journal of Infectious Diseases|September 11, 2019
Immunogenicity, Lot Consistency, and Extended Safety of rVSVΔG-ZEBOV-GP Vaccine: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study in Healthy AdultsScott A Halperin, Rituparna Das, Matthew T Onorato, et al.
The Lancet. Infectious Diseases|March 21, 2026
Safety, tolerability, and immunogenicity of a 31-valent pneumococcal conjugate vaccine (VAX-31) in healthy adults aged 50 years and older from the USA: a phase 1/2, double-blinded, active-controlled, parallel-group, dose-finding randomised clinical trialJames Wassil, Jeff Fairman, Carlos A Fierro, et al.
Vaccine|July 22, 2008
Evaluation of widely consumed botanicals as immunological adjuvantsGovind Ragupathi, K Simon Yeung, Ping-Chung Leung, et al.
Neurorehabilitation|May 1, 2023
Stakeholder perspectives on navigating the pediatric concussion experience: Exploring the needs for improved communication across the care continuumDouglas Gomez, Ann Glang, Juliet Haarbauer-Krupa, et al.
Vaccine|January 18, 2022
Lot-to-lot consistency, safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in healthy adults aged ≥50 years: A randomized phase 3 trial (PNEU-TRUE)Jakub K Simon, Nina Breinholt Staerke, Maria Hemming-Harlo, et al.
The Lancet. Infectious Diseases|December 7, 2023
Evaluating the safety, tolerability, and immunogenicity of a 24-valent pneumococcal conjugate vaccine (VAX-24) in healthy adults aged 18 to 64 years: a phase 1/2, double-masked, dose-finding, active-controlled, randomised clinical trialJames Wassil, Maggie Sisti, Jeff Fairman, et al.
Pageof 74